Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other...

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Activating point mutations in the MET tyrosine kinase domain (TKD) are oncogenic drivers in certain cancers, notably papillary renal cell carcinoma.
• The MET pathway plays a crucial role in cell proliferation, survival, and migration, making it a significant target in cancer research.

Purpose of the Study:

• To identify the frequency and spectrum of activating MET TKD point mutations across a broad range of cancer types.
• To investigate the oncogenic potential of these mutations through preclinical modeling and assess their sensitivity to MET inhibitors.
• To explore the clinical efficacy of MET inhibitors in patients with MET TKD-mutated cancers.

Main Methods:

• Comprehensive genomic profiling of over 600,000 patients to identify MET TKD mutations.
• Preclinical modeling using cell lines and/or animal models to validate oncogenic potential and drug sensitivity.
• Clinical case studies of patients with metastatic lung adenocarcinoma harboring MET TKD mutations treated with MET inhibitors.

Main Results:

• Activating MET TKD point mutations were identified as putative oncogenic drivers in approximately 0.5% of diverse cancers.
• Common oncogenic mutations involve amino acid substitutions at key positions (e.g., H1094, L1195, F1200, D1228, Y1230, M1250).
• Preclinical models confirmed oncogenic potential and differential sensitivity to type I and type II MET inhibitors. Two patients with lung adenocarcinoma harboring MET TKD mutations responded to a type I MET inhibitor.

Conclusions:

• Activating MET TKD mutations are present across multiple cancer types and represent a targetable genomic subset.
• These mutations confer sensitivity to currently available MET tyrosine kinase inhibitors, supporting their use in precision oncology.
• The findings highlight the importance of comprehensive genomic profiling for identifying patients who may benefit from targeted MET-directed therapies.